Navigation Links
OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
Date:11/21/2011

HOUSTON, Nov. 21, 2011 /PRNewswire/ -- OrthoAccel® Technologies, Inc. announced this week that it has finalized a distribution agreement with Micerium S.p.A. based in Avegno for exclusive distribution rights of the AcceleDent™ System in Italy.

The AcceleDent™ System is currently being sold outside the USA and was first introduced in the United Kingdom in October 2009.  The lightweight appliance, used to speed up the rate of orthodontic treatment, is intended for 20 minutes of daily use.  Patients simply bite down on the Mouthpiece to hold it in place, which allows freedom of the hands to engage in other routine, daily activities during the treatment session.  Patients have reported using the appliance while engaged in a variety of activities, including homework, watching television, reading and listening to music.

Mike Kaufman, Vice President of Marketing and Business Development for OrthoAccel® commented, "Micerium is the most recent addition to our growing network of European distributors.  Italy is a key international market for us and it bodes well that this market leader shares our philosophy and excitement for how AcceleDent™ can change orthodontic treatment."  AcceleDent™ was introduced to the Italian orthodontic community during the SIDO meeting in Rome November 11-13.  Dr. Ravindra Nanda reported on the recent results from a randomized, controlled clinical trial conducted at the University of Texas Health Science Center at San Antonio under the guidance of Dr. Dubravko Pavlin where AcceleDent™ demonstrated, with statistical significance, that tooth movement could be safely accelerated by 38% to 50% during space closure and even more so during the alignment phase.

This definitive distribution agreement between OrthoAccel® and Micerium formalizes the intent to partner together that was initiated under a Terms of Agreement in June of this year.  Ottaviano Miceli, CEO of Micerium, expressed his enthusiasm, "I am excited about this new project. Our company has always paid attention to market innovations and we believe that AcceleDent is great news - a simple product that will bring many benefits to the orthodontic treatment in terms of time savings and results. In a short time we have already seen a great interest and desire to discover and try AcceleDent by the Italian orthodontists who want to offer the best treatment to their patients. " 

OrthoAccel® has been selling the AcceleDent™ System outside the USA since October 2009.  FDA clearance is pending based on an application submitted earlier this year.

About OrthoAccel® Technologies, Inc.
Based in Houston, Texas, OrthoAccel® Technologies, Inc. is a privately owned medical device company currently engaged in the development, manufacturing, and marketing of products to enhance dental care and orthodontic treatment.

About the
AcceleDent™ System
AcceleDent™
represents the first clinical approach to safely accelerate orthodontic tooth movement via modulating bone biology. The device has been studied clinically and applies gentle pulsing forces in combination with standard orthodontics to move teeth faster through accelerated bone remodeling. Importantly, the device works complementary with all existing orthodontic technologies. AcceleDent™ is neither FDA cleared nor FDA approved; it is currently investigational only in the United States. More information can be found at www.acceledent.com and www.acceledent.co.uk or requested via info@orthoaccel.com


'/>"/>
SOURCE OrthoAccel Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
3. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
4. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
5. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
6. Arbios Sells HepatAssist Bioartificial Liver System to HepaLife Technologies, Inc.
7. Advanced Analytical Technologies, Inc. Expands Into New Office and Production Space
8. AVAX Technologies, Inc. Announces Closing of Bridge Loan Financing
9. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
10. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
11. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):